Alethio Therapeutics, a University of Oxford spin-out developing treatments for a group of blood cancers called myeloproliferative neoplasms (MPNs), raised $90m (£67m) in an oversubscribed Series A round announced on 5 November 2026.
Sofinnova Partners and RA Capital Management co-led the round, both as new investors, according to EU-Startups. Oxford Science Enterprises, which backed the company at its founding, took part along with Cancer Research Horizons and the University of Oxford.
Graziano Seghezzi, a managing partner at Sofinnova, and Maxwell DeNies of RA Capital are joining Alethio's board. The company did not disclose a valuation.
“Too often, a patient's first encounter with ET is a thrombotic event that lands them in the emergency room”Rohit Batta, CEO, Alethio Therapeutics
What Alethio is developing
MPNs are cancers in which the bone marrow makes too many blood cells. Alethio's lead drug, ATX-011, is a first-in-class antibody that targets a protein called G6B. It is aimed at essential thrombocythaemia (ET), a form of MPN in which the body makes too many platelets, which raises the risk of blood clots.
"Too often, a patient's first encounter with ET is a thrombotic event that lands them in the emergency room," said chief executive Rohit Batta. Speaking to BioPharma Dive, he compared the disease to "an accelerator stuck down, constant drive, no brake".
ATX-011 is in the studies needed before a drug can be tested in people, and preclinical data was chosen for an oral presentation at the American Society of Hematology's 2026 meeting. BioPharma Dive reported that the drug is expected to enter clinical testing in the first half of 2028.
Alethio also has a programme aimed at mutant calreticulin, a protein that EU-Startups said is involved in about 30% of MPN cases, and a discovery platform it calls ARTEMIS. BioPharma Dive also reported work on an antibody-drug conjugate targeting G6B for myelofibrosis.
Who founded it
The company was founded by Professors Adam Mead and Beth Psaila, physician-scientists who study MPNs at Oxford. EU-Startups reported that it was spun out in 2021. Its press release is datelined Oxford; EU-Startups and BioPharma Dive place it in Abingdon, Oxfordshire.
Seghezzi said: "The most transformative companies are built around insights that challenge long-held assumptions in medicine." DeNies said RA Capital was "drawn to the strength of the biology underpinning Alethio's approach".
A crowded field
MPNs include primary myelofibrosis, essential thrombocythaemia and polycythaemia vera. Patients today are treated with regular blood withdrawals, hydroxyurea, interferon therapies and JAK inhibitors such as Incyte's Jakafi, and Takeda's Mimrylo was recently approved for polycythaemia vera, BioPharma Dive reported. Incyte, Merck & Co. and Novartis are all active in the field. Batta said existing treatments still do not help most patients.
Alethio estimates that ET affects about 150,000 people in the US, more than its estimates for polycythaemia vera and primary myelofibrosis combined. G6B is found on platelets and on certain bone marrow cells that drive MPNs or bone marrow scarring, which the company believes could let ATX-011 work whichever mutation is driving a patient's disease.
Seghezzi told BioPharma Dive that targeting ET could give the drug more reach than approved treatments for other MPNs. "The key words are we're not controlling the disease, we're treating it," he said.
What the money is for
Alethio said the funding will make it a clinical-stage company. It plans to run ATX-011 through a Phase 1/2a trial in ET with the aim of being ready for a Phase 3 study, and to move further MPN programmes towards an investigational new drug filing.
The company did not disclose earlier funding, its total raised or its headcount.
Company website: alethiotherapeutics.com
